{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:04:49Z","timestamp":1763010289152,"version":"3.45.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>IVIG therapy may be clinically beneficial following lung transplantation (LTx), either by correcting hypogammaglobulinemia or by mitigating the humoral response to the lung allograft. However, the evidence base in LTx is limited. We aimed to recruit 40 LTx patients into a pilot placebo-controlled study of adding IVIG therapy to standard immunosuppression. The primary aim of the study was to provide feasibility data to inform the subsequent design of a definitive phase 2\/3 randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Stable patients were recruited between 3 and 6 mo post-LTx to receive 6 monthly infusions of either IVIG (0.4\u2009g\/kg) or placebo. Patients were followed for 12 mo. Primary study outcomes were related to feasibility; namely, the proportion of patients who (1) were screened to be eligible, (2) were eligible and enrolled, (3) lost to follow-up, and (4) received their allocated treatment. Although clinical data were collected, the study was not designed or powered to detect significant differences in clinical or adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Recruitment into the study was significantly impacted by the COVID pandemic. The final study cohort either received IVIG (n\u2005=\u200518) or placebo (n\u2005=\u200519). Four patients on IVIG did not receive the full complement of 6 study infusions because of infusion reactions. Otherwise, there was no significant difference in the safety profile between the 2 study arms. Four patients, all randomized to placebo, were unblinded because of clinical concerns and started on open-label IVIG. Serum IgG levels increased, and the incidence of hypogammaglobulinemia was lower in the IVIG-treated arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>The use of IVIG was relatively well tolerated in LTx recipients. The extracted clinical and safety data support consideration and the design of a definitive multicenter randomized controlled trial of IVIG in LTx.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration.<\/jats:title>\n                    <jats:p>Australian and New Zealand Clinical Trial Registry: ACTRN12618001394235.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/txd.0000000000001880","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:02:36Z","timestamp":1763010156000},"page":"e1880","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Randomized Double-blind Placebo-controlled Feasibility Study of IVIG Therapy in Lung Transplantation"],"prefix":"10.1097","volume":"11","author":[{"given":"Glen P.","family":"Westall","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Alfred Health, Melbourne, Australia."},{"name":"Department of Medicine, School of Translational Medicine, Monash University, Melbourne, VIC, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobenguni","family":"Ndiweni","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Alfred Health, Melbourne, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-2175","authenticated-orcid":false,"given":"Kovi","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Alfred Health, Melbourne, Australia."},{"name":"Department of Medicine, School of Translational Medicine, Monash University, Melbourne, VIC, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-4249","authenticated-orcid":false,"given":"Bronwyn","family":"Levvey","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Alfred Health, Melbourne, Australia."},{"name":"Department of Medicine, School of Translational Medicine, Monash University, Melbourne, VIC, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-3669","authenticated-orcid":false,"given":"Gregory I.","family":"Snell","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Alfred Health, Melbourne, Australia."},{"name":"Department of Medicine, School of Translational Medicine, Monash University, Melbourne, VIC, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"R1-20251113","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.healun.2013.10.022","article-title":"A new classification system for chronic lung allograft dysfunction.","volume":"33","author":"Verleden","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R2-20251113","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00007890-200101270-00013","article-title":"Hypogammaglobulinemia in lung transplant recipients.","volume":"71","author":"Goldfarb","year":"2001","journal-title":"Transplantation"},{"key":"R3-20251113","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/01.TP.0000159136.72693.35","article-title":"Risk factors and outcomes of hypogammaglobulinemia after lung transplantation.","volume":"27","author":"Kawut","year":"2005","journal-title":"Transplantation"},{"key":"R4-20251113","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.healun.2012.10.006","article-title":"Bronchiolitis obliterans syndrome, hypogammaglobulinemia, and infectious complications of lung transplantation.","volume":"32","author":"Chambers","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"R5-20251113","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R6-20251113","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.healun.2004.11.016","article-title":"The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study.","volume":"24","author":"Yamani","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R7-20251113","doi-asserted-by":"crossref","first-page":"e103908","DOI":"10.1371\/journal.pone.0103908","article-title":"Intravenous immunoglobulin for hypogammaglobulinemia after lung transplantation: a randomized crossover trial.","volume":"9","author":"Lederer","year":"2014","journal-title":"PLoS One"},{"key":"R8-20251113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.trim.2014.06.004","article-title":"Evolving experience of treating antibody-mediated rejection following lung transplantation.","volume":"31","author":"Otani","year":"2014","journal-title":"Transpl Immunol"},{"key":"R9-20251113","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/00007890-199612150-00024","article-title":"Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation.","volume":"62","author":"Peraldi","year":"1996","journal-title":"Transplantation"},{"key":"R10-20251113","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/TP.0000000000000339","article-title":"Nonspecific immunoglobulin replacement in lung transplantation recipients with hypogammaglobulinemia: a cohort study taking into account propensity score and immortal time bias.","volume":"99","author":"Claustre","year":"2015","journal-title":"Transplantation"},{"key":"R11-20251113","first-page":"99","article-title":"The Alfred Hospital lung transplant experience.","author":"Paraskeva","year":"2014","journal-title":"Clin Transpl"},{"key":"R12-20251113","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.healun.2007.10.017","article-title":"Revision of the 1996 working formulation for the standardization of the nomenclature in the diagnosis of lung rejection.","volume":"26","author":"Stewart","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R13-20251113","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.healun.2016.01.1223","article-title":"Antibody-mediated rejection of the lung: a consensus report of the International Society of Heart and Lung Transplantation.","volume":"35","author":"Levine","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R14-20251113","first-page":"493","article-title":"Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment\u2014a consensus report from the Pulmonary Council of the ISHLT.","volume":"38","author":"Glanville","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R15-20251113","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy.","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"R16-20251113","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence.","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R17-20251113","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1542\/peds.2007-1218","article-title":"Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.","volume":"121","author":"Manlhiot","year":"2008","journal-title":"Pediatrics"},{"key":"R18-20251113","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1423-0410.2003.00336.x","article-title":"Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity.","volume":"85","author":"Thorpe","year":"2003","journal-title":"Vox Sang"},{"key":"R19-20251113","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-1471","article-title":"Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin diseases: high efficacy and no serious adverse events.","volume":"93","author":"Seidling","year":"2013","journal-title":"Acta Derm Venerol"},{"key":"R20-20251113","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CND.0b013e3182212589","article-title":"The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.","volume":"12","author":"Souayah","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"R21-20251113","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1053-2498(00)00331-4","article-title":"Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection.","volume":"20","author":"Yamani","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"R22-20251113","doi-asserted-by":"crossref","first-page":"e13625","DOI":"10.1111\/ctr.13625","article-title":"Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis. Part II: non-kidney transplant.","volume":"33","author":"Bourassa-Blanchette","year":"2019","journal-title":"Clin Transplant"},{"key":"R23-20251113","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1526924818817028","article-title":"Detrimental association of hypogammaglobulinemia with chronic lung allograft dysfunction and death is not mitigated by on-demand immunoglobulin G replacement therapy after lung transplantation.","volume":"29","author":"Lichvar","year":"2019","journal-title":"Prog Transplant"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:02:40Z","timestamp":1763010160000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001880","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}